- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 211/62 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
Patent holdings for IPC class C07D 211/62
Total number of patents in this class: 451
10-year publication summary
|
38
|
35
|
32
|
27
|
24
|
25
|
32
|
24
|
26
|
20
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Theravance Biopharma R&D IP, LLC | 360 |
20 |
| Biogen MA Inc. | 942 |
18 |
| Novartis AG | 10174 |
14 |
| The Regents of the University of California | 20868 |
10 |
| The Broad Institute, Inc. | 1991 |
10 |
| Eli Lilly and Company | 4117 |
10 |
| Eisai R&D Management Co., Ltd. | 1163 |
10 |
| ChemoCentryx, Inc. | 361 |
9 |
| Bayer Cropscience AG | 1833 |
8 |
| Massachusetts Institute of Technology | 10290 |
8 |
| The General Hospital Corporation | 4881 |
8 |
| Bristol-myers Squibb Company | 4757 |
6 |
| Boehringer Ingelheim International GmbH | 4488 |
6 |
| Merck Sharp & Dohme Corp. | 2183 |
5 |
| Alkermes Pharma Ireland Limited | 255 |
5 |
| Araxes Pharma LLC | 90 |
5 |
| Dainippon Sumitomo Pharma Co., Ltd. | 164 |
5 |
| Global Blood Therapeutics, Inc. | 167 |
5 |
| Hovione Scientia Limited | 127 |
5 |
| Intellia Therapeutics, Inc. | 245 |
5 |
| Other owners | 279 |